We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Invest in DexCom (DXCM) Stock Now
Read MoreHide Full Article
DexCom, Inc. (DXCM - Free Report) is well poised for growth on the back of lucrative glucose monitoring market, solid international market presence and robust product portfolio.
The stock carries a Zacks Rank #2 (Buy).
Price Performance
Shares of DexCom have gained 37.9%, against the industry’s decline of 3.8% in a year’s time. The stock also outpaced the S&P 500 Index’s increase of 1.1%.
What’s Favoring the Stock?
DexCom continues to gain from the lucrative and growing glucose monitoring market that presents substantial commercial opportunity. Per an article of Research and Markets, the blood glucose monitoring devices market is expected to witness a CAGR of over 9% between 2018 and 2024.
Moreover, the company boasts of a robust product portfolio, which in turn has been bolstering its overall performance. Per management, the company is well poised to achieve long-term target on the back of the expansion of the rollout of G6 and improve access to CGM. With this growing demand in mind, the company is on track to meet its goal of doubling G6 capacity by the end of 2019.
DexCom continues to benefit from strong international presence and is eyeing the sizeable markets of Korea, India, China and Japan. If we go by statistics then more than half of the diabetic population in developing nations remain undiagnosed. Consequently, the company can boost sales by expanding into overseas territory, where the momentum is anticipated to continue in the future.
Additionally, the company’s strategic collaborations and buyouts continue to bolster growth. DexCom has collaborative agreements with several companies, which should not only bring in cash in the form of milestone payments and royalties but should also help expand product use.
Which Way Are Estimates Headed?
For 2019, the Zacks Consensus Estimate for revenues is pegged at $1.29 billion, indicating an improvement of 24.7% from the year-ago period. The same for earnings stands at 80 cents per share, suggesting growth of 166.7% from the year-ago reported figure.
Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33.3%.
Quidel Corporation has a long-term earnings growth rate of 25%.
Heamonetics has a long-term earnings growth rate 13.5%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Here's Why You Should Invest in DexCom (DXCM) Stock Now
DexCom, Inc. (DXCM - Free Report) is well poised for growth on the back of lucrative glucose monitoring market, solid international market presence and robust product portfolio.
The stock carries a Zacks Rank #2 (Buy).
Price Performance
Shares of DexCom have gained 37.9%, against the industry’s decline of 3.8% in a year’s time. The stock also outpaced the S&P 500 Index’s increase of 1.1%.
What’s Favoring the Stock?
DexCom continues to gain from the lucrative and growing glucose monitoring market that presents substantial commercial opportunity. Per an article of Research and Markets, the blood glucose monitoring devices market is expected to witness a CAGR of over 9% between 2018 and 2024.
Moreover, the company boasts of a robust product portfolio, which in turn has been bolstering its overall performance. Per management, the company is well poised to achieve long-term target on the back of the expansion of the rollout of G6 and improve access to CGM. With this growing demand in mind, the company is on track to meet its goal of doubling G6 capacity by the end of 2019.
DexCom continues to benefit from strong international presence and is eyeing the sizeable markets of Korea, India, China and Japan. If we go by statistics then more than half of the diabetic population in developing nations remain undiagnosed. Consequently, the company can boost sales by expanding into overseas territory, where the momentum is anticipated to continue in the future.
Additionally, the company’s strategic collaborations and buyouts continue to bolster growth. DexCom has collaborative agreements with several companies, which should not only bring in cash in the form of milestone payments and royalties but should also help expand product use.
Which Way Are Estimates Headed?
For 2019, the Zacks Consensus Estimate for revenues is pegged at $1.29 billion, indicating an improvement of 24.7% from the year-ago period. The same for earnings stands at 80 cents per share, suggesting growth of 166.7% from the year-ago reported figure.
Key Picks
Some better-ranked stocks from the broader medical space are Cardiovascular Systems, Inc. , Quidel Corporation (QDEL - Free Report) and Heamonetics Corporation (HAE - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33.3%.
Quidel Corporation has a long-term earnings growth rate of 25%.
Heamonetics has a long-term earnings growth rate 13.5%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>